Chemicals stocks · Micro cap · NSE
Privi Speciality Chemicals is India's leading manufacturer of aroma chemicals, with a 30+ year track record in pine-based and specialty products. It supplies top fragrance and FMCG companies globally, leveraging 7 manufacturing facilities, 2 R&D centers, and 70% renewable raw materials.
MACD − · sector -4.2pp vs Nifty 500 (3M)
Latest mapped FPI equity flow was not positive. View sector evidence
Adjusted completed-session prices, rebased to 100
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is consistent.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Revenue +19.1% · PAT +43.1% YoY
Price trend and sector-relative-strength timing.
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Financial-only signal; management claim evidence is not sufficient yet.
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Rev +19% YoY · PAT +43% YoY · operating leverage · margin compression
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹666 Cr | +19.1% | -7.8% |
| EBITDA | ₹152 Cr | +15.2% | -15.6% |
| Operating margin | 23.0% | -100 bps | -200 bps |
| PAT | ₹83 Cr | +43.1% | -11.7% |
| PAT margin | 12.5% | +208 bps | -56 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Updated 21/10/2026
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Trend is weak — long-term uptrend intact. RSI 34.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
U-Score 66 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Top U-Score contributors and drags from the latest stored fundamentals.
Cyclical companies can look cheapest near peak profits, so IndiaPulse flags value-trap risk separately.
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
12 stored score snapshots. Latest stored move: +0 points.
Business-comparable peers in Chemicals — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Growth engines, risks, management commitments and evidence-backed delivery
Privi Speciality Chemicals reported strong FY26 performance with total income up 21.7% YoY to 2,583 Cr and PAT up 75.2% YoY to 327.54 Cr. Q4FY26 also saw robust growth, with total income up 15.5% YoY and PAT up 40.9% YoY, driven by volume growth and improved product mix.
Strong FY26 financial performance, including significant revenue and PAT growth, improved margins, and substantial debt reduction, supports the ongoing investment thesis. Management's 5k:1k vision and strategic initiatives like the PRIGIV JV indicate continued growth potential and focus on value-added products.
Expanding the reach of current products to increase sales.
Introducing new products, in synergy with existing raw materials, including Maltol, Ethyl Maltol, Renewable Cyclopentanone, and Furfural.
Dedicated product portfolio manufacturing 40+ specialty products exclusively for Givaudan, achieved positive PAT in Q4 FY26.
Privi Biotechnologies Private Limited (PBPL) specializes in biotechnology-driven flavour and fragrance development, aligning with green science vision.
Undertook debottlenecking initiatives in FY26 to support future growth and enhance capacity utilization.
PRIGIV JV commissioned and commenced commercial production at Mahad, MH.
Evaluating additional CAPEX to manufacture high-value specialty molecules using in-house technology, with potential revenue of ~ 100+ crore.
Flagship product capacity augmentation project nearing completion.
Rising urbanization and changing consumer lifestyles are boosting the consumption of fragrance-based products.
Preference for bio-based and eco-friendly aroma chemicals is reshaping product innovation and market positioning.
Rising affluence and premiumization are driving fragrance usage in personal care and home care.
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
The presentation provides both quarterly (Q4FY26 vs Q4FY25) and annual (FY26 vs FY25) comparisons. Annual figures are crucial for assessing overall business trajectory and the impact of strategic initiatives, while quarterly data shows recent momentum.
FY26: 2,582.92 Cr (+21.7% YoY); Q4FY26: 725.70 Cr (+15.5% YoY)
FY26: 25.8% (+342 bps YoY); Q4FY26: 25.4% (+195 bps YoY)
FY26: 327.54 Cr (+75.2% YoY); Q4FY26: 93.7 Cr (+40.9% YoY)
FY26: 550.09 Cr
Focused on disciplined execution and delivering on the 5k:1k vision ( 5,000 Cr revenue and 1,000 Cr+ EBITDA) over the medium term (by FY29-30).
Strong emphasis on profitability and long-term value creation, with EBITDA margins expected to sustain north of 20%.
Continue to see encouraging traction in value-added and specialty products, supported by focused investments in capability building.
Sustainability remains integral to the approach, with continued emphasis on responsible manufacturing and process innovation.
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Revenue | 2,582.92 Cr (FY26) | Progress towards 5,000 Cr by FY29-30. |
| EBITDA | 665.45 Cr (FY26) | Progress towards 1,000 Cr+ by FY29-30. |
| EBITDA Margin | 25.8% (FY26) | Sustained margins north of 20%. |
| Net Debt to Equity | 0.62x (FY26) | Continued reduction in debt levels. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 94th percentile of the scored universe and 91st percentile within Chemicals. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
overall median 67 · Chemicals: 91st pctile, median 73 · Micro: 90th pctile, median 73
56 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Latest exchange and company disclosures found within the past two years.
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse
Source: Bse